.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
This randomized trial directly compared gastric bypass with sleeve gastrectomy in adults with moderately obese, poorly controlled type 2 diabetes. The study asked whether the two operations produce similar metabolic effects even when performed in patients who do not necessarily meet the very highest BMI thresholds associated with bariatric surgery. At one year, diabetes remission was markedly more frequent after gastric bypass than after sleeve gastrectomy in the study population. Both procedures produced metabolic improvements, but bypass demonstrated a stronger effect on glycaemic control. The findings are clinically relevant because they reinforce the concept of metabolic surgery as a therapeutic option for selected patients with type 2 diabetes, not simply as a treatment for severe obesity. At the same time, the trial was relatively small and had a short follow-up compared with major long-term bariatric studies, so its findings should be interpreted within the broader evidence base. For surgeons, procedure selection should remain individualized. Diabetes duration, endogenous insulin reserve, BMI, reflux, nutritional risk and patient preferences all influence the choice between procedures. The practical lesson is that sleeve gastrectomy and gastric bypass can have different metabolic profiles, and the patient's dominant clinical problem—not weight alone—should inform operative planning.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
This randomized trial directly compared gastric bypass with sleeve gastrectomy in adults with moderately obese, poorly controlled type 2 diabetes. The study asked whether the two operations produce similar metabolic effects even when performed in patients who do not necessarily meet the very highest BMI thresholds associated with bariatric surgery. At one year, diabetes remission was markedly more frequent after gastric bypass than after sleeve gastrectomy in the study population. Both procedures produced metabolic improvements, but bypass demonstrated a stronger effect on glycaemic control. The findings are clinically relevant because they reinforce the concept of metabolic surgery as a therapeutic option for selected patients with type 2 diabetes, not simply as a treatment for severe obesity. At the same time, the trial was relatively small and had a short follow-up compared with major long-term bariatric studies, so its findings should be interpreted within the broader evidence base. For surgeons, procedure selection should remain individualized. Diabetes duration, endogenous insulin reserve, BMI, reflux, nutritional risk and patient preferences all influence the choice between procedures. The practical lesson is that sleeve gastrectomy and gastric bypass can have different metabolic profiles, and the patient's dominant clinical problem—not weight alone—should inform operative planning.
Yesterday
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
